- Breakthrough scientific research paves the way for field
trials of cattle vaccine for bovine tuberculosis (bTB)
- Environment Secretary hails ‘significant milestone’ in
long-term plan to eradicate the disease
- Cattle vaccine trials form part of wider bTB control strategy
including badger vaccination, phasing out culling and improved
testing
World-leading bovine tuberculosis (bTB) TB cattle vaccination
trials are set to get underway in England and Wales as a result
of a major breakthrough by government scientists.
These trials enable work to accelerate towards planned deployment
of a cattle vaccine by 2025, in the latest milestone to eradicate
this highly damaging animal disease and allow us to phase out
culling.
bTB is one of the most difficult and intractable animal health
challenges that England and Wales face today. More than 40,000
cattle are slaughtered each year due to infection from bTB.
However, a cattle vaccination could become a powerful tool in the
battle against the disease following the necessary testing and
subsequent approvals to ensure its safety and efficacy.
It is one of several key elements of the long-term bTB strategy
to eradicate the disease by 2038. Measures include plans to phase
out intensive badger culling, improve the cattle testing regime
and vaccinate more badgers against the disease and improved
testing to intercept bTB earlier.
The field trials will be conducted over the next four years on
behalf of Defra, the Welsh Government and the Scottish
Government, following 20 years of ground-breaking research into
bovine TB vaccines and diagnostic tests.
Environment Secretary said:
“Bovine TB is a slow-moving and insidious disease which can cause
considerable trauma for farmers as they suffer the loss of highly
prized animals and valued herds.
“This scientific breakthrough is a major step forwards in our
battle to see the disease eradicated from this country. As wider
preventative measures like cattle vaccines are introduced, we
will accelerate other elements of our strategy and start to phase
out badger culling, as no one wants to continue the cull of a
protected species indefinitely.”
The UK Chief Veterinary Officer Christine Middlemiss said:
“The Animal Plant and Health Agency’s ground-breaking research
has been pivotal in developing this potential vaccine. Whilst
there is no single way to combat this damaging and complex
disease, cattle vaccination is a potential new tool for our
multi-pronged approach to tackle it and importantly prevent it,
providing vital support to our farming communities.
“Bovine TB presents a global challenge and the UK has harnessed
its world-leading science to develop potential solutions such as
vaccination and new diagnostic tests that could also be valuable
to other countries.”
Development of a deployable cattle BTB vaccine was a top priority
outlined in the
government’s response to
an independent review of its 25 year bTB strategy, led by
Professor Sir Charles Godfray. The response to the Godfray Review
set out plans to phase out intensive culling in the next few
years, and outlined the need for a combined approach which
includes badger and cattle vaccination to eradicate the disease
by 2038.
British Veterinary Association Junior Vice President James
Russell said:
“The deployment of a viable cattle vaccine used in combination
with a validated DIVA test has the potential to be an absolute
game changer in our efforts to control and eradicate bovine
tuberculosis, and is something that our own expert bTB working
group’s upcoming report has identified as a key priority.
“These field trials mark the culmination of years of
ground-breaking research and efforts by the veterinary scientific
community to expand the range of tools available to vets and
farmers to tackle bovine tuberculosis.”
The latest statistics on bTB in England show the overall number
of new herd incidents of the disease is down by 9% in the last
year (to Nov 2019), a 10% reduction in the number of herds not
officially free of the disease and a 4% reduction in the total
number of animals slaughtered due to the disease. Full details of
these statistics are
available here.